- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01032135
Adaptive Treatment for Alcohol and Cocaine Dependence
Primary objective #1: Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use over weeks 1-24.
- Hypothesis 1: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce higher rates of treatment engagement than an intervention focused on engagement in IOP only (e.g., MI-IOP).
- Hypothesis 2: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce better cocaine/alcohol use outcomes than an intervention focused on engagement in IOP only (MI-IOP).
- Secondary analysis 1: Among the Non-engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option.
- Secondary analysis 2: Among the Engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option.
Primary objective #2: Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use outcomes over weeks 1-24.
- Hypothesis 1: The predicted main effect on retention favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
- Hypothesis 2: The predicted main effect on cocaine/alcohol use outcomes favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
3. Secondary objective #1: Examine outcomes on three secondary measures: percent days abstinent from all substances, negative consequences of drug use, and HIV high risk behaviors.
Hypothesis 1: Outcomes on the secondary measures will be better in MI-PC than in MI-IOP.
4. Secondary objective #2: Test hypotheses concerning potential mediators of the predicted main effect favoring MI-PC over MI-IOP.
Hypothesis 1: The predicted advantage of MI-PC over MI-IOP will be mediated by greater increases in motivation, self-efficacy, commitment to abstinence, and self-help involvement in MI-PC.
5. Secondary objective #3: Test hypotheses concerning effect of additional MI intervention after initial non-engagement persists through 12 weeks.
- Hypothesis 1: A second telephone MI intervention will produce higher rates of subsequent engagement and less cocaine use than no further MI.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Presbyterian Medical Center
-
Philadelphia, Pennsylvania, États-Unis, 19123
- NorthEast Treatment Center
-
Philadelphia, Pennsylvania, États-Unis, 19104
- VAMC
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- meet DSM-IV criteria for lifetime cocaine or alcohol dependence and have used cocaine or alcohol in the prior 6 months;
- be > 18 years of age;
- be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment;
- have no regular IV heroin use during the past year;
- have access to a telephone;
- be willing to be randomized and participate in research; and
- no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will
- be required to be metropolitan area residents, and
- be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.
Exclusion Criteria:
- have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment;
- have acute medical problem requiring immediate inpatient treatment; or
- are currently participating in methadone or other forms of DA treatment, other than IOP.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 1-MI-IOP Engaged
Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Autres noms:
|
|
Expérimental: 2-MI-IOP Non-Engaged
Randomized to treatment as usual, and do not attend.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Autres noms:
one telephone counseling session per week for 10 weeks.
Autres noms:
One CBT session per week, for 10 weeks.
Autres noms:
Prescription for naltrexone
Autres noms:
Return to IOP, group therapy 3 times weekly for about three hours a day.
Autres noms:
|
|
Comparateur actif: 3-MI-PC Engaged
Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Autres noms:
one telephone counseling session per week for 10 weeks.
Autres noms:
One CBT session per week, for 10 weeks.
Autres noms:
|
|
Expérimental: 4-MI-PC Non-engaged
Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Autres noms:
one telephone counseling session per week for 10 weeks.
Autres noms:
One CBT session per week, for 10 weeks.
Autres noms:
Prescription for naltrexone
Autres noms:
Return to IOP, group therapy 3 times weekly for about three hours a day.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Treatment Engagement
Délai: weeks 3 - 12
|
Number of treatment sessions attended
|
weeks 3 - 12
|
|
Treatment Engagement for Participants Engaged at 2 Weeks, But Disengage Before 8 Weeks
Délai: weeks 9 - 12
|
Number of treatment sessions attended
|
weeks 9 - 12
|
|
Treatment Engagement of Those Non-engaged at 2 Weeks and at 8 Weeks
Délai: weeks 9 - 12
|
Number of treatment sessions attended
|
weeks 9 - 12
|
|
Any Drinking Days in Previous Month
Délai: Month 2 (weeks 5 - 8 post baseline)
|
Days of any drinking in previous month, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Any Drinking Days in Previous Month
Délai: Month 3 (weeks 9 - 12 post baseline)
|
Any drinking days during previous month, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Drinking
Délai: Month 4 (weeks 13 - 15 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 4 (weeks 13 - 15 post baseline)
|
|
Any Drinking
Délai: Month 5 (weeks 16 - 20 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back, This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 5 (weeks 16 - 20 post baseline)
|
|
Any Drinking
Délai: Month 6 (weeks 21 - 24 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Drinking
Délai: Month 2 (weeks 5 - 8 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Percent Days Drinking
Délai: Month 3 (weeks 9 - 12 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Drinking
Délai: Month 4 (weeks 13 - 16 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Percent Days Drinking
Délai: Month 5 (weeks 17 - 20 post baseline)
|
Percent days of any drinking at follow up, fromTime Line Follow Back
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Percent Days Drinking
Délai: Month 6 (weeks 21 - 24)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 6 (weeks 21 - 24)
|
|
Any Heavy Drinking Days
Délai: Month 2 (weeks 5 - 8 post baseline)
|
days of five or more drinks per drinking day for men, four or more drinks per drinking day for women, at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Any Heavy Drinking Days
Délai: Month 3 (weeks 9 - 12 post baseline)
|
five or more drinks per drinking day for men, four or more drinks per drinking day for women, at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Heavy Drinking Days
Délai: Month 4 (weeks 13 - 16 post baseline)
|
five or more drinks per drinking day for men, four or more drinks per drinking day for women at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Any Heavy Drinking Days
Délai: Month 5 (weeks 17 to 20 post baseline)
|
five or more drinks per day for men, four or more drinks per day for women, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 5 (weeks 17 to 20 post baseline)
|
|
Any Heavy Drinking Days
Délai: Month 6 (weeks 21 - 24 post baseline)
|
five or more drinks per day for men, four or more drinks per day for women, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Heavy Drinking
Délai: Month 2 (weeks 5 - 8 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per day for men, four or more for women |
Month 2 (weeks 5 - 8 post baseline)
|
|
Percent Days Heavy Drinking
Délai: Month 3 (weeks 9 - 12 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back * heavy drinking is defined as five or more drinks per day for men, four or more for women. |
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Heavy Drinking
Délai: Month 4 (weeks 13 - 16 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 4 (weeks 13 - 16 post baseline)
|
|
Percent Days Heavy Drinking
Délai: Month 5 ( weeks 17 - 20 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back * heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 5 ( weeks 17 - 20 post baseline)
|
|
Percent Days Heavy Drinking
Délai: Month 6 (weeks 21 - 24 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 6 (weeks 21 - 24 post baseline)
|
|
Any Cocaine Use
Délai: Month 3 (weeks 9 - 12 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Cocaine Use
Délai: Month 4 (weeks 13 - 16 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Any Cocaine Use
Délai: Month 5 (weeks 17 - 20 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Any Cocaine Use
Délai: Month 6 (weeks 21 - 24 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Cocaine Use
Délai: Month 3 (weeks 9 - 12 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Cocaine Use
Délai: Month 5 (weeks 17 - 20 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Percent Days Cocaine Use
Délai: Month 6 (weeks 21 - 24 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 6 (weeks 21 - 24 post baseline)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: James R. McKay, Ph.D, University of Pennsylvania
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 807092
- IND: 101,486
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .